CompletedPhase 4NCT03497689

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Studying Idiopathic pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
United Therapeutics
Principal Investigator
Chad E Miller, MD
Piedmont Healthcare Pulmonary and Critical Care Research
Intervention
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil(drug)
Enrollment
36 enrolled
Eligibility
18-75 years · All sexes
Timeline
20192022

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03497689 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary arterial hypertension

← Back to all trials